The Inflation Reduction Act (IRA) will impact the pricing of drugs in the US, and decisions around indication sequencing and life cycle management will have a big impact on overall revenue projections.
The IRA further complicates decision making particularly in oncology drug development, where one asset is typically developed for multiple indications in a typical ‘late-line first, larger opportunity in early line later’ sequency. The impact of the IRA will be felt on an asset and portfolio level in different ways, so it is important that this be taken into consideration when developing a commercialization strategy.
During this webinar, we will explore:
– Strategies and considerations to re-think drug development in oncology in this new post-IRA world
– Considerations around launch geography
– Therapeutic modality impact (small molecule vs. biologics)
– Balancing patient needs and pricing demands
Join us as we discuss the importance of adjusting and rethinking the traditional paradigm in a post-IRA world.
